Lipid nanoparticles for targeted cancer therapies
The Tow Foundation Postdoctoral Fellowship (2022-present)
NIH T32 Cancer Pharmacology Training Grant (2020-2022)
I am a multidisciplinary scientist, devoted to biomedical research since my undergraduate studies in Chemical Engineering, at the National Technical University of Athens, Greece. During my Ph.D. at ETH Zurich, Switzerland, I studied the biophysical aspects of cancer metastasis, using nano- and micro-fabrication tools to create artificial platforms mimicking human tissue. After my Ph.D., I worked as an R&D Manager for two years in a diagnostics startup company, where I monitored the activities of a team of 10 scientists and engineers, focusing on the product’s clinical development. During this time, I set up from scratch two complete, functional research labs (cell culture lab and chemical synthesis and characterization).
I moved to the United States and joined MSKCC’s Molecular Pharmacology Program in late 2020, in the middle of the pandemic. In the Cancer Nanomedicine Lab, I develop nanoparticle drug delivery systems for the targeted treatment of cancer or acute kidney injury. Acute kidney injury, for which no approved drugs exist, is a common side effect of cancer therapies and can dramatically increase patients’ morbidity and mortality.